EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).

Trial Profile

EPREX (Epoetin Alfa) Versus ARANESP (Darbepoetin Alfa): Looking at Outcome of Anemia Treatment and Comparing Cost-effectiveness (EVALUATE).

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jun 2014

At a glance

  • Drugs Epoetin alfa (Primary) ; Darbepoetin alfa
  • Indications Anaemia
  • Focus Therapeutic Use
  • Acronyms EVALUATE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 04 Apr 2012 Actual patient number changed from 494 to 492 added as reported by ClinicalTrials.gov.
    • 04 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top